The much-anticipated arrival of Sutent (sunitinib) in the oncology space occurred last week - and did so with a bang: It received FDA approval for two indications at once, an agency first for a cancer product. (BioWorld Today)

The much-anticipated arrival of Sutent (sunitinib) in the oncology space occurred last week - and did so with a bang: It received FDA approval for two indications at once, an agency first for a cancer product. (BioWorld Today)

Metabolon Inc., a low-key company specializing in biomarkers for drugs and diagnostics, raised $8 million in a Series B funding round that closed last week.

Metabolon Inc., a low-key company specializing in biomarkers for drugs and diagnostics, raised $8 million in a Series B funding round that closed last week.